Company news
Xenon Pharmaceuticals Inc. news in 2022
Xenon Pharmaceuticals Inc.'s news releases, calls and decks from 2022, newest first.
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
December 1, 2022
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
November 29, 2022
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
November 8, 2022
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 7, 2022
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary
November 6, 2022
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
November 2, 2022
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
October 31, 2022
Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
August 31, 2022
Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 8, 2022
Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
August 7, 2022
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update
August 1, 2022
Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022
July 10, 2022
Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 26, 2022
Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program
June 21, 2022
Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering
June 21, 2022
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
June 20, 2022
Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
May 31, 2022
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 9, 2022
Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)
May 2, 2022
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update
May 2, 2022
Xenon Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
April 3, 2022
Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days
March 21, 2022
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
February 28, 2022
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update
February 21, 2022
Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 13, 2022
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
January 11, 2022
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022
January 9, 2022
Calls in 2022
- Xenon Pharmaceuticals (NASDAQ:XENE) Q3 2022 Earnings Call
Nov 8, 2022
Transcript - Xenon Pharmaceuticals (NASDAQ:XENE) Q2 2022 Earnings Call
Aug 9, 2022
Transcript - Xenon Pharmaceuticals (NASDAQ:XENE) Q1 2022 Earnings Call
May 10, 2022
Transcript - Xenon Pharmaceuticals (NASDAQ:XENE) Q4 2021 Earnings Call
Mar 1, 2022
Transcript